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ABSTRACT
Decrease in bone mineral density (BMD) has been a complication among people living 
with HIV/AIDS. To investigate the prevalence of osteopenia/osteoporosis among HIV-infected 
people living in São Paulo city, we studied 108 HIV-infected patients (79 men and 29 women). 
We extracted data from patients’ medical records and BMD was measured by dual-energy 
X-ray absorptiometry (DXA). Median age of participants was 42 years (interquartile range 
[IQR] 36-48 years), and the median time since HIV diagnosis was 4.01 years (IQR 2-11 years). 
Patients had acquired HIV primarily by the sexual route (men who have sex with men 44%, 
heterosexual 49%). Median age, duration of HIV infection, duration of ART and CD4 nadir 
were similar for men and women. Plasma viral load was undetectable for 53 patients (49%). 
Median CD4 T cell count was 399 cells/µL (IQR 247 - 568). Twenty five patients (23%) 
had LBMD, and there was no statistically significant difference between men and women 
(<-1). The associated risk factors for LBMD were older age (> 50 years old) and smoking 
with a RR of 3.87 and 2.80, respectively. Thus, despite the lack of statistically significant 
relationship between the use of ART and LBMD or between duration of ART and LBMD, 
these factors should be addressed in larger studies. 
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INTRODUCTION
The HIV-infected population has aged, especially when engaged long-time 
survival, even in developing countries, such as Brazil, which have adopted universal 
access to ART since middle 90’s1.One of these new challenges is the chronic 
metabolic disturbances, such as diabetes, hypertension, metabolic syndrome and 
deregulation of bone metabolism2.
The pathogenesis of bone demineralization in HIV infection is unclear3. Possible 
explanations include a direct action of the infection itself4, an untoward effect of 
the antiretroviral therapy (ART)5, a deregulation of bone metabolism as a result of 
the T-CD4 cell depletion6, or a consequence of other risk factors for osteoporosis 
that are more prevalent among people with HIV such as poor nutrition or smoking7. 
Identifying modifiable risk factors may be the key for designing simple interventions 
and preventing significant clinical morbidity. 
In a middle-income country such as Brazil, bone demineralization is an important 
cause of morbidity, even in the absence of HIV infection. For example, from 2006 
to 2008, 1% of all patients aging 60 years old and older who were hospitalized in 
the Unified National Health System (SUS) had a primary diagnosis of hip fracture, 
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and they accounted for 2% of health care expenditures8. The 
mean cost of hospitalization for a hip fracture is $12,000 
in the Brazilian private health care system9. Thus, as the 
HIV-infected population ages as a result of successful 
ART10,11, osteopenia and osteoporosis, both of them effects 
of HIV infection and aging, have the potential to become 
substantial public health burdens12, and their prevention 
becomes an important public health goal. We studied the 
prevalence of low bone mineral density (LBMD), and risk 
factors in a population of 108 HIV-infected patients under 
follow-up at a referral center in São Paulo, Brazil. 
MATERIAL AND METHODS
Subjects
The study population was composed of HIV-1-infected 
patients attended at the outpatient clinic for secondary 
immunodeficiencies of Hospital das Clínicas, University 
of São Paulo Medical School (HC/FMUSP), São Paulo, SP, 
Brazil, a large teaching and research hospital. This open 
patient cohort was composed of 455 active HIV1-infected 
subjects under follow-up for up to 16 years. Description 
of the cohort and its characteristics have been published 
elsewhere13,14. All patients were invited to participate, 108 
accepted. The study protocol was approved by the Hospital 
das Clínicas Review Board and all patients gave written 
informed consent.
Predictor variables
Our predictor variables included sex, age, time since 
HIV diagnosis, CD4 cells/µL, CD4 nadir, plasma viral 
load, current use of ART, body mass index [BMI], current 
smoking status and physical activity. These variables 
were extracted from clinical charts. For analyzes, we 
dichotomized the age into <50 years and >50 years, CD4 
count into <350 cells/µL and >350 cells/µL, CD4 nadir into 
<170 cells/µL and >170 cells/µL, time since HIV diagnosis 
into <4 years and >4 years, plasma viral load into detectable 
or non-detectable and time on ART as <5 years or >5 years. 
However, classes of ART drugs were not considered in detail 
on this report, therefore, no further information for their use 
is provided in the report.
Bone mineral density measurement and categorization
Our primary outcome variable was LBMD, which we 
measured using dual X-ray absorptiometry of the lumbar 
spine, femoral neck and total hip (Hologic, QDR 4500, 
Discovery model, Hologic Inc. Bedford, MA, USA). 
All measurements of bone mineral density (BMD) were 
performed by the same experienced technician (LT). We 
classified post-menopausal women and men > 50 years 
old as having osteoporosis or osteopenia based on World 
Health Organization criteria. Subjects with a BMD T-score 
between -1 and -2.5 were categorized as having osteopenia, 
and subjects with a BMD T-score less than or equal to -2.5 
were categorized as having osteoporosis. For the purposes 
of this study, any participant with osteopenia or osteoporosis 
according to the WHO definition wasconsidered to have 
LBMD. This classification has been extensively used by 
other authors5,15-17. 
Statistical analysis
We calculated the prevalence of LBMD with 95% 
confidence intervals (CI), and evaluated the association 
of LBMD with its potential risk factors by calculating the 
relative risks. 
RESULTS 
We enrolled 108 patients of whom 78 (72%) were men 
and 30 (28%) were women. The median age was 43 years 
(interquartile range [IQR]: 43 - 48), and the median BMI 
was 24 kg/m2 (IQR: 22 – 27)..LBMD was detected in 15% 
(95% CI: 6 – 22) of patients younger than 50 years old and 
54% (95% CI: 32 – 77) of those who were 50 years old and 
older. The median follow-up period from the date of HIV 
infection diagnosis was 4 years (95% CI: 2- 11); 74% of the 
patients were on ART for a median time of 5.12 years (IQR: 
2.59 – 10.12). The median CD4 counts and median nadir 
for CD4 counts were 399 cells/µL (IQR: 275 – 566.5) and 
176.5 cells/µL (IQR: 73 – 309), respectively. Participants 
enrolled in the study did not differ significantly from the 
remainder of patients followed in the Hospital das Clinicas 
cohort (Table 1).
The overall prevalence of LBMD was 23.15% (95% 
CI, 15.06 – 31.23%), of them 15 (60%) HIV-1-infected had 
osteopenia and 10 (40%) HIV-1-infected had osteoporosis. 
The risk of LBMD was higher in subjects >50 years of 
age (14.45% vs. 54.54%, RR 3.77, 95% CI, 1.97 – 7.02, 
p=0.001), those with T CD4 counts <350 cells/µL (15.87% 
vs. 33.33%, RR 2.1, 95% CI 1.03-4.24, p=0.03) and current 
smokers (39.28% vs. 17.94%, RR 2.18, 95% CI 1.12 – 4.23, 
p=0.02) (Table 2). 
DISCUSSION
We found that the overall prevalence of LBMD in our 
patients who had been on ART for a median of 5 years was 
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23.15%. Previous studies have estimated that the prevalence 
of osteopenia and osteoporosis in Brazilian patients with 
HIV infection was 54.5%5. This discrepancy could be 
related to different methodologies used in these studies, 
thus leading to these discordant results.
The CD4 cell count <350 cells/µL which was a risk 
factor for LBMD had not been previously reported and 
may indicate that the longer the duration of infection or 
the less successful the ART, the higher the likelihood 
of developing LBMD. Additionally, we did not find a 
statistically significant relationship between the use of ART 
and LBMD or between the duration of ART and LBMD, 
although both relationships have been already reported18,19. 
As mentioned before, osteoporosis was associated with 
HIV infection duration, low current or low nadir CD4 
cell count or high viral load, for example20. Cazanave et 
al.21 showed that low nadir CD4 lymphocyte count was 
independently associated with osteoporosis/osteopenia in 
women, demonstrating that these alterations were induced 
by early bone demineralization. 
In fact, HIV-infected infected subjects have lower BMI 
than HIV-negative control groups, as described previously22. 
Several reports demonstrated that habit of smoking, and 
lifestyle, traditional known risk factors for osteoporosis, 
are also important in this population23,24. Furthermore, 
reduced BMD was also significantly associated with low 
25-hidroxy-calciferol in this cohort25. Thus, smoking 
reduction, physical activity26 and other life changes may 
have an impact on bone disease.
Our study was limited by its small sample size, which 
may have led to a type II error. Larger and more regularly 
sampled cohorts may yield different results. Nonetheless, 
our findings are compelling and suggest that addressing 
modifiable risk factors for LBMD and fractures might 
constitute important interventions as Brazilian HIV-infected 
patients age, especially for those who are already older 
than 50 years old.
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Table 1 - Demographic, clinical and behavioral characteristics 
according to low BMD, among 108 HIV-infected patients 
attending an outpatient HIV clinic, São Paulo, Brazil
Variables N= 108 patients
LBMD 25 23.15%
Gender
    Female 30 (27.78%)
    Male 78 72.22%
Age median (IQR) 43,17 43.17-48.19
    >50 Years 22 20.37%
    ≤50 years 83 76.86%
HIV transmission
    Homosexual 50 46%
    Heterosexual 54 50%
    Others 4 3.70%
T CD4 cells Median (IQR) 399 275-566.5
    ≤ 350 cells /mm3 45 41.67%
    ≤ 350 cells /mm3 45 41.67%
Nadir median (IQR) 176,5 73-309
    <170 cells /mm3 50 46.30%
    ≥170 cells /mm3 58 53.70%
Time since HIV diagnostic (IQR) 3,66 1.72-10.91
    >4 years 49 45.37%
    ≤ 4 years 55 50.93%
Viral load 
    Detectable 52 48.15%
    Undetectable 53 49.09%
Under ART
    Yes 80 74.07%
    No 28 25.93%
Years under ART
    >5 years 41 51.25%
    ≤ 5 years 36 45%
Smoking
    Yes 28 25.93%
    No 78 72.22%
Physical Activity
    No 72 66.67%
    Yes 34 31.48%
BMI
    ≤25 54 50%
    >25 35 32.41%
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